SCHEMBL228911

SCHEMBL228911

COc1cc2c(c(OC)c1)C(=O)CCC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
ACHE P22303 1/20 0.51
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
EGFR P00533 4/20 0.42
NFE2L2 Q16236 2/20 0.42
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1274286 0.89 ALDH1A1 (0.55) MEN1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL11030544 0.84 BRD4 (0.46) MEN1KMT2AALDH1A1ACHEMAPT
SCHEMBL22815495 0.84 MEN1 (0.41) MEN1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL25307258 0.83 EGFR (0.42) MEN1KMT2AALDH1A1ACHEEGFR
SCHEMBL30550465 0.83 EGFR (0.42) MEN1KMT2AALDH1A1ACHEEGFR
SCHEMBL21052196 0.81 PTGS2 (0.53) MEN1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL21098689 0.81 EGFR (0.41) MEN1KMT2AALDH1A1EGFRNFE2L2
SCHEMBL15898570 0.81 ALDH1A1 (0.42) MEN1KMT2AALDH1A1CYP1A2MAPT
SCHEMBL24755482 0.81 EGFR (0.41) MEN1KMT2AALDH1A1EGFRNFE2L2
SCHEMBL7340707 0.81 KDM4E (0.54) ALDH1A1ACHEMAPTEGFRELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111909083-B Inhibitors of histone demethylase 赛尔基因昆蒂赛尔研究公司 2023-08-15 CN disclosed
EP-3160952-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-12-02 EP disclosed
EP-3160952-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-12-02 EP disclosed
EP-3741749-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-25 EP disclosed
EP-3741749-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-25 EP disclosed
EP-3738960-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-18 EP disclosed
EP-3738960-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-18 EP disclosed
CN-111909083-A Histone demethylase inhibitors 赛尔基因昆蒂赛尔研究公司 2020-11-10 CN disclosed
CN-106660982-B Histone demethylase inhibitors 赛尔基因昆蒂赛尔研究公司 2020-09-08 CN disclosed
US-10385047-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-08-20 US disclosed
US-4310669-A TETRALONE PFIZER INC. (US) 1982-01-12 US disclosed
US-4310668-A Intermediates to 1,9-dihydroxyoctahydrophenanthrenes PFIZER INC. (US) 1982-01-12 US disclosed
US-4270005-A ANALGESICS PFIZER INC. (US) 1981-05-26 US disclosed
US-4268523-A ANALGESICS PFIZER INC. (US) 1981-05-19 US disclosed
US-4268692-A ANALGESICS PFIZER INC. (US) 1981-05-19 US disclosed
US-4237133-A ANALGESICS PFIZER INC. (US) 1980-12-02 US disclosed
US-4188495-A 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor PFIZER INC. (US) 1980-02-12 US disclosed
US-4169108-A 5(OR 6)-[(Substituted-amino)alkyl]-2,3-naphthalenediols STERLING DRUG INC. (US) 1979-09-25 US disclosed
US-3951959-A VAGINOTROPIC SCHERING AKTIENGESELLSCHAFT (DT) 1976-04-20 US disclosed
US-3951958-A VAGINOTROPIC SCHERING AKTIENGESELLSCHAFT (DT) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385047-B2 Histone demethylase inhibitors KDM1B, KDM6A, KDM1A MEN1 3059/4885KMT2A 47/4885ALDH1A1 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.